{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:15Z","timestamp":1792096875056,"version":"4.4.0"},"reference-count":77,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become available, we envision a multi-pronged treatment strategy that simultaneously targets the consequences of ongoing nephron loss, stopping any glomerular inflammation, inhibiting pro-fibrotic signals in the glomerulus and tubulo-interstitium, and inhibiting the production of pathogenic IgA molecules. This review is an update on a previous review published in 2021, and we aim to summarize the developments and updates in therapeutic strategies in IgAN and highlight the promising discoveries that are likely to add to our armamentarium.<\/jats:p>","DOI":"10.3390\/jcm13040947","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:12:58Z","timestamp":1707286378000},"page":"947","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["An Update on Current Therapeutic Options in IgA Nephropathy"],"prefix":"10.3390","volume":"13","author":[{"given":"Regina Shaoying","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-4781","authenticated-orcid":false,"given":"See Cheng","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UK"},{"name":"John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester LE5 4PW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, ZRB 614, 1720 2nd Avenue South, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: An interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00005792-199403000-00002","article-title":"IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature","volume":"73","author":"Ibels","year":"1994","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy","volume":"8","author":"Radford","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1440-1797.2004.00255.x","article-title":"Immunosuppressive treatments for immunoglobulin A nephropathy: A meta-analysis of randomized controlled trials","volume":"9","author":"Samuels","year":"2004","journal-title":"Nephrology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-Term Outcomes in IgA Nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 100, S1\u2013S276."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Wright, J.T., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.M., Rahman, M., and Oparil, S. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 373, 2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_17","unstructured":"Nuffield Department of Population Health Renal Studies Group, and SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Consortium, Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: New perspectives and recent findings","volume":"25","author":"Speed","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref_22","unstructured":"Novartis (2023, November 30). Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN). Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-investigational-atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107701","DOI":"10.1016\/j.pharmthera.2020.107701","article-title":"Mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"219","author":"Cosimato","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bolignano, D., Palmer, S.C., Navaneethan, S.D., and Strippoli, G.F. (2014). Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev., CD007004.","DOI":"10.1002\/14651858.CD007004.pub3"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","first-page":"935","article-title":"Steroid therapy in IgA nephropathy: A prospective pilot study in moderate proteinuric cases","volume":"61","author":"Kobayashi","year":"1986","journal-title":"Q. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000188848","article-title":"Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study","volume":"72","author":"Kobayashi","year":"1996","journal-title":"Nephron"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2215\/CJN.0000000000000263","article-title":"Selecting Treatment for IgA Nephropathy","volume":"18","author":"McGuire","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_35","first-page":"123","article-title":"IgA nephropathy","volume":"76","author":"McCoy","year":"1974","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000184350","article-title":"Composition of mesangial deposits in IgA nephropathy: Complement factors","volume":"46","author":"Bene","year":"1987","journal-title":"Nephron"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.1987.72","article-title":"Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis","volume":"31","author":"Rauterberg","year":"1987","journal-title":"Kidney Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_42","unstructured":"Omeros Corporation (2023, November 30). Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy. Available online: https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-provides-update-interim-analysis-artemis-igan."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2023","journal-title":"Kidney Int."},{"key":"ref_44","unstructured":"Pharmaceuticals, A. (2023, December 16). Arrowhead Announces Interim Results from Ongoing Phase 1\/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases. Available online: https:\/\/ir.arrowheadpharma.com\/news-releases\/news-release-details\/arrowhead-announces-interim-results-ongoing-phase-12-study-aro."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014An open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2023","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cheung, C.K., Barratt, J., Carroll, K., Lafayette, R.A., Liew, A., Suzuki, Y., Tesar, V., Trimarchi, H., Wong, M.G., and Zhang, H. (2023). Targeting APRIL in the Treatment of IgA Nephropathy. Clin. J. Am. Soc. Nephrol., epub ahead of print.","DOI":"10.2215\/CJN.0000000000000338"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression","volume":"82","author":"Zhao","year":"2012","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.1047","article-title":"A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy","volume":"44","author":"Yu","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ekir.2022.01.121","article-title":"POS-109 Interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"gfad063a_3848","DOI":"10.1093\/ndt\/gfad063a_3848","article-title":"#3848 Origin trial: 24-wk primary analysis of a randomized, double-blind, placebo-controlled PH2B study of atacicept in patients with igan","volume":"38","author":"Lafayette","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients with IgA Nephropathy with Persistent Proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Maixnerova, D., El Mehdi, D., Rizk, D.V., Zhang, H., and Tesar, V. (2022). New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102810"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of Mycophenolate Mofetil Among Patients with Progressive IgA Nephropathy: A Randomized Clinical Trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"646650","DOI":"10.3389\/fimmu.2021.646650","article-title":"The Role of Renal Macrophage, AIM, and TGF-beta1 Expression in Renal Fibrosis Progression in IgAN Patients","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/ndt\/gfh323","article-title":"Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy","volume":"19","author":"Leung","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_75","first-page":"747","article-title":"Primary IgA nephropathy is more severe in TGF-beta1 high secretor patients","volume":"22","author":"Brezzi","year":"2009","journal-title":"J. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.HYP.0000153791.89776.43","article-title":"Transforming growth factor-beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats","volume":"45","author":"Sharma","year":"2005","journal-title":"Hypertension"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","article-title":"Antifibrotic Agents for the Management of CKD: A Review","volume":"80","author":"Lamas","year":"2022","journal-title":"Am. J. Kidney Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/947\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:20Z","timestamp":1760104580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13040947"],"URL":"https:\/\/doi.org\/10.3390\/jcm13040947","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}